Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-effic...
Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
About this item
Full title
Author / Creator
Publisher
United States: National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently to the nucleus and is targeted for degradation by...
Alternative Titles
Full title
Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_jstor_primary_25462687
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_jstor_primary_25462687
Other Identifiers
ISSN
0027-8424
E-ISSN
1091-6490
DOI
10.1073/pnas.0802866105
